What technical advantages does NGS offer over Sanger SBT for high-resolution assays?

The critical difference lies in the resolution of diploid DNA. Next‑Generation Sequencing (NGS) overcomes the core technical limitations of Sanger Sequence‑Based Typing (SBT) by definitively resolving heterozygous phase, covering entire gene targets without gaps, and indexing dozens of patient samples in a single run. For high‑resolution molecular diagnostic assays, these three advantages directly eliminate ambiguous allele calls, reduce reflex testing, and massively increase laboratory throughput.

When diagnostic precision demands phased whole‑gene information and high sample volumes, NGS is the unambiguous choice. It transforms a fragmented, single‑exon, low‑throughput process into a single‑molecule, full‑coverage, multiplexed workflow that delivers definitive results where Sanger SBT cannot.

Resolving Immunogenetic Complexity Without Compromise

The true challenge in high‑resolution typing isn’t sequencing a sequence—it’s sequencing two sequences at once. Sanger SBT cannot separate maternal and paternal alleles when they differ, and its narrow target selection leaves critical variants unseen. NGS addresses both failures at their root.

Untangling Heterozygous Phase Ambiguity

When a diploid sample is heterozygous at multiple positions, Sanger sequencing produces overlapping chromatogram peaks. The diagnostic interpreter cannot determine which variant belongs to which chromosome—a problem known as phase ambiguity. This leads to ambiguous allele assignments that require labor‑intensive follow‑up tests.

NGS eliminates this by sequencing individual DNA molecules. Long‑range PCR first amplifies entire gene regions (4–10 kb). Enzymatic fragmentation then creates a library of single‑stranded fragments, each originating from one parental allele. By sequencing these molecules in parallel, NGS directly observes the true cis arrangement of polymorphisms. Phase is resolved during the assay, not retroactively guessed.

Eliminating Sequence Gaps and Hidden Variants

Sanger SBT often sequences only a handful of “critical” exons—in many immunogenetic loci, just exons 2 and 3. Variants outside these windows remain completely invisible. The result is a high rate of ambiguous typing that demands costly reflex sequencing of additional exons or even different methods.

NGS assay panels are designed to capture the entire gene, from promoter to 3′ untranslated region. Intronic polymorphisms and regulatory variants that affect expression or splicing are captured alongside exonic ones. By clearing up the dark matter of the gene, NGS reduces ambiguous allele calls to near zero and removes the need for iterative, single‑exon reflex testing.

Drastically Increasing Throughput via Sample Multiplexing

In a Sanger SBT workflow, each sample runs in a single capillary. Throughput is physically capped by the number of capillaries and the sequential nature of the process. NGS, in contrast, uses sample‑specific barcode sequences that are ligated during library preparation.

Dozens to hundreds of uniquely barcoded patient libraries are then pooled onto a single flow cell or sequencing chip. The sequencer reads all of them simultaneously, and the barcodes are used to demultiplex the reads afterward. This single‑run, parallel‑batch model optimizes reagent consumption, reduces hands‑on time, and makes it economically feasible to perform full‑gene high‑resolution typing on large cohorts.

Detecting Low‑Frequency Variant Subpopulations

For many diagnostic applications—such as HIV resistance genotyping or drug‑resistance monitoring in tuberculosis—high‑resolution means seeing minor variants that represent only a small fraction of the total viral or bacterial population. Sanger SBT typically exhibits a detection limit of about 20 % variant allele frequency. Rare mutants below this threshold are simply invisible.

NGS workflows, built with high‑fidelity polymerases and deep sequencing coverage, routinely achieve analytical sensitivities well below 1 %. This enables early detection of emergent resistance mutations that would otherwise be missed, directly informing more effective treatment decisions. The same deep‑sequencing capability also enables accurate variant calling in heterogeneous tumor samples or chimeric specimens, areas where Sanger SBT would generate un‑interpretable noise.

Understanding the Trade‑offs

NGS’s technical superiority in these dimensions does not mean it is the optimal choice for every diagnostic scenario. Objectively assessing the trade‑offs is essential.

Workflow Complexity and Bioinformatics Demand

NGS requires specialized library preparation steps, quality control, and a bioinformatics pipeline for alignment, variant calling, and phasing. This infrastructure is more complex than the “load‑and‑run” simplicity of a Sanger capillary instrument. Laboratories must invest in both wet‑lab and computational expertise.

Cost Structure and Batch Size

While NGS has a dramatically lower cost per base, its overall run cost is relatively fixed. If you only need to type a single gene in a handful of samples per week, Sanger SBT may be more economical. NGS becomes cost‑advantageous when batch sizes are large enough to leverage multiplexing and when the alternative would include the hidden expense of repeated reflex testing.

Sanger Remains a Gold‑Standard Confirmatory Tool

For simple, monogenic applications—such as verifying a known single‑nucleotide mutation in a single colony or completing a small‑scale viral genome—Sanger’s workflow simplicity and long single‑read length still hold value. It remains the method of choice for validating individual NGS‑detected variants when ultra‑high sensitivity is not required.

Making the Right Choice for Your Assay Goal

The decision between NGS and Sanger SBT should be driven by the assay’s informational demand and operational scale.

• If your primary focus is resolving heterozygous phase and eliminating ambiguous allele calls: Choose NGS. Its single‑molecule readout directly assigns maternal and paternal haplotypes, something Sanger SBT cannot do.
• If your primary focus is complete gene coverage to avoid reflex testing: Choose an NGS panel that spans entire gene regions. This eliminates the diagnostic uncertainty inherent in multi‑exon, reflex‑based Sanger workflows.
• If your primary focus is high‑volume, multi‑sample throughput: Leverage NGS sample barcoding to pool dozens of patients in a single run. This drastically reduces cost per sample and hands‑on labor compared to sequential Sanger runs.
• If your primary focus is detecting minority variants below 20 % frequency: NGS’s deep‑sequencing sensitivity is indispensable; Sanger’s detection floor will miss clinically relevant low‑abundance mutations.
• If your primary focus is a low‑volume, single‑gene confirmation test: Sanger SBT remains a fast and reliable choice. Reserve NGS for applications where its resolution, coverage, and multiplexing advantages directly translate into clinical clarity.

Mastering the choice between these technologies is not about picking a “better” platform, but about aligning the tool’s inherent strengths with the exact diagnostic question you need to answer.

Summary Table:

Whether you are designing high-resolution molecular diagnostic assays or scaling laboratory throughput, CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Ready to accelerate your assay development? Contact CamelBio today to discuss your diagnostic solutions with our team.